Equity Research

Economics Weekly: 2022 Outlook Shifting into the Midcycle

Whether it actually turns out to be more mild, as bad, or worse than the Delta variant, the latest COVID variant—the Omicron strain—is yet another reminder that the virus has not gone away, that it does mutate, and that those mutations might make the current vaccines less effective. The fact that it has emerged from the Southern African states, where vaccination rates are very low, is also a reminder that without broader global support from the developed market economies in terms of vaccines, it will be very difficult to fully eradicate the virus. It also comes as a poignant reminder about the risks to growth in the coming year as we start to think about how the economy is likely to develop.

With this in mind, in this Economics Weekly, we discuss the outlook for growth, inflation, monetary policy, and financial market performance. While we are optimistic about the outlook over the coming year, Omicron is yet another reminder that nothing is set in stone and events may be subject to change without notice—as such, “viewer discretion is advised.”

For a copy of this report or to subscribe to the Economics Weekly or Economic Indicators reports, please contact your William Blair representative.

Richard de Chazal, CFA is a London-based macroeconomist covering the U.S. economy and financial markets.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news

Our Latest News

2022 Top Stock Recommendations

Each year, the Equity Research Group's individual sector groups—consumer; financial services and technology; global industrial infrastructure; global services; healthcare; and technology, media, and communications—provide an outlook for the year ahead.

Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures